Amadeus Capital Partners is a global technology investor with over $1bn raised since 1997, backing 190+ pioneering companies. From AI to cybersecurity and biotech, their investments drive transformative innovation worldwide.

Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, fostering early-stage biotech innovation. Home to major players like GSK and LifeArc, along with a thriving start-up ecosystem, companies on campus have raised over £3.6bn in funding.

Accelerate Cambridge, run by Cambridge Judge Business School, provides a structured 3-month accelerator programme with training, coaching, and mentoring—at no cost or equity. Situated at the heart of Cambridge’s innovation ecosystem, it supports entrepreneurs in developing and scaling their ventures with a hands-on, experience-driven approach.

o2h Ventures is a biotech specialist tax-efficient fund manager focused on investing in novel drug therapeutics, AI/ML drug discovery platforms & biotech enablers. With 35+ early-stage biotech companies in their portfolio, they are empowering impactful research in areas like cancer, depression, diseases of the ear and eye, psoriasis, idiopathic pulmonary fibrosis, anti-aging and Infectious diseases.

Meltwind Advisory, founded by Jonathan Milner, fosters a collaborative ecosystem to bring breakthrough life science innovations to market. As his due diligence and portfolio management team, they support companies with investment and strategic guidance to drive transformative health outcomes.

Accelerate@Babraham, the bio-incubator at Babraham Research Campus, nurtures early-stage life science ventures with expert mentorship, investor networks, and strategic business support. Recognised as one of Europe’s top 25 biotech incubators, it has supported 32 companies, helping them raise £72.5m with a portfolio value exceeding £139m.